We are proud to share with you that the trademark “NOL NOCICEPTION LEVEL INDEX” is approved and registered as Medasense’s trademark in the Europe and in the US!
We are excited to share that Medasense’s technology was chosen to be highlighted in the British Journal of Anaesthesia (BJA) review article “Digital innovations and emerging technologies for enhanced recovery programmes”.
We are pleased to share with you the exciting news that Medasense has received AMAR approval to sell our pain (Nociception) monitoring system in Israel!
Israeli anesthesiologists are now able to join their European colleagues, who are
Medasense featured in Innovations in Pharmaceutical Technology publication.
Read our article written by CEO, Galit Zuckerman-Stark, to learn how an objective approach could help healthcare professionals better assess pain.
Medasense headlines “Anesthesiology News” – the most-read publication by anesthesiologists in the USA!!
The article reports on clinical trial results previously published in Anesthesiology in 2016, with insightful interviews from lead investigators, Dr. Daniel Sessler (Head of Center of Outcomes Research, Cleveland Clinic, Ohio, USA) and Dr. Ruth Edry (Department of Anesthesiology, Rambam Medical Centre, Haifa, Israel).
Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™.
This new technology is now available to help physicians objectively assess a patient’s pain in critical care situations, where